ZA200607471B - Materials and methods for treatment of allergic disease - Google Patents

Materials and methods for treatment of allergic disease

Info

Publication number
ZA200607471B
ZA200607471B ZA200607471A ZA200607471A ZA200607471B ZA 200607471 B ZA200607471 B ZA 200607471B ZA 200607471 A ZA200607471 A ZA 200607471A ZA 200607471 A ZA200607471 A ZA 200607471A ZA 200607471 B ZA200607471 B ZA 200607471B
Authority
ZA
South Africa
Prior art keywords
treatment
materials
methods
allergic disease
allergic
Prior art date
Application number
ZA200607471A
Other languages
English (en)
Inventor
Walker William
Hopkin Julian Meurglyn
Original Assignee
Allema Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allema Ltd filed Critical Allema Ltd
Publication of ZA200607471B publication Critical patent/ZA200607471B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200607471A 2004-02-25 2006-09-07 Materials and methods for treatment of allergic disease ZA200607471B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0404209.9A GB0404209D0 (en) 2004-02-25 2004-02-25 Materials and methods for treatment of allergic disease

Publications (1)

Publication Number Publication Date
ZA200607471B true ZA200607471B (en) 2008-05-28

Family

ID=32050868

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607471A ZA200607471B (en) 2004-02-25 2006-09-07 Materials and methods for treatment of allergic disease

Country Status (9)

Country Link
US (1) US7566700B2 (fr)
EP (1) EP1725658B1 (fr)
JP (1) JP2007523658A (fr)
AU (1) AU2005217200B2 (fr)
CA (1) CA2599524C (fr)
GB (1) GB0404209D0 (fr)
NZ (1) NZ549915A (fr)
WO (1) WO2005083083A2 (fr)
ZA (1) ZA200607471B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064625A2 (fr) 2002-02-01 2003-08-07 Sequitur, Inc. Compositions oligonucleotidiques presentant une efficacite amelioree
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
US20060258610A1 (en) * 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
TW201336514A (zh) 2006-04-13 2013-09-16 Alcon Res Ltd ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
JP2010068723A (ja) * 2008-09-16 2010-04-02 Tokyo Medical & Dental Univ アレルギー疾患の治療のための核酸医薬
WO2010107958A1 (fr) * 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. INHIBITION INDUITE PAR ARN INTERFÉRENCE DE L'EXPRESSION DU GÈNE TRANSDUCTEUR DE SIGNAL ET ACTIVITATEUR DE TRANSCRIPTION 6 (STAT6) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (ANsi)
GB201511459D0 (en) * 2015-06-30 2015-08-12 Cell Therapy Ltd Sirna microbubble

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705212D0 (en) 1997-03-13 1997-04-30 Ciba Geigy Ag Chemical compounds
WO2003025138A2 (fr) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
CA2460625A1 (fr) * 2001-10-12 2003-04-17 Incyte Genomics, Inc. Proteines structurales et associees au cytosquelette
US20050222057A1 (en) * 2001-10-15 2005-10-06 Himanshu Brahmbhatt Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US20040115634A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals, Inc. Modulation of stat 6 expression
CA2538215A1 (fr) * 2003-09-30 2005-04-07 Anges Mg, Inc. Oligonucleotide du type en agrafe et medicament comprenant celui-ci
CN1922197A (zh) * 2004-02-20 2007-02-28 吉尼西斯研究及发展有限公司 用于治疗IgE介导的失调的RNA干涉分子的靶向递送

Also Published As

Publication number Publication date
US20080234212A1 (en) 2008-09-25
CA2599524C (fr) 2015-06-02
CA2599524A1 (fr) 2005-09-09
EP1725658B1 (fr) 2014-04-09
EP1725658A2 (fr) 2006-11-29
NZ549915A (en) 2009-08-28
WO2005083083A3 (fr) 2005-10-20
JP2007523658A (ja) 2007-08-23
AU2005217200B2 (en) 2010-05-06
US7566700B2 (en) 2009-07-28
AU2005217200A1 (en) 2005-09-09
WO2005083083A2 (fr) 2005-09-09
GB0404209D0 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
ZA200607471B (en) Materials and methods for treatment of allergic disease
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
IL213843A0 (en) 4-aminotetracyclines and methods of use thereof
EP1761204A4 (fr) Dispositif implantable pour le traitement de maladies et procedes d'utilisation
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
GB0404345D0 (en) Surgical jig and methods of use
EP1827391A4 (fr) Formes posologiques et procedes d'utilisation de celles-ci
IL180600A0 (en) Compositions and methods of use for treatment of mammalian diseases
EP1909689A4 (fr) Implants contenant un medicament et leur procede d'utilisation
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
IL179931A0 (en) Compositions and methods for treatment of cardiovascular disease
EP1931390A4 (fr) Compositions et methodes de traitement de maladies auto-immunes
EP1786265A4 (fr) Nouvelles compositions et procedes de traitement
EP1789047A4 (fr) Procede pour traiter des maladies au moyen de nalmefene et de ses analogues
HK1171972A1 (zh) 治療疾病的方法和產品
EP1812451A4 (fr) Composes et methodes d'utilisation de ces composes
EP1954800A4 (fr) Composition et utilisation d'un phyto-percolate pour le traitement d'une maladie
EP1928247A4 (fr) Composition et utilisation de phyto-percolate pour le traitement d'une maladie
EP1765331A4 (fr) Procedes et compositions destines au traitement de maladies pulmonaires
EP1805210A4 (fr) Nouveaux peptides et procédés pour le traitement de maladie inflammatoire
ZA200709024B (en) Method of well treatment and construction
EP1773882A4 (fr) Diagnostic et traitement de maladies associees a siglec-6
EP1924286A4 (fr) Procédé thérapeutique et/ou phropylactique pour le traitement d'une maladie auto-immune
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
GB0504657D0 (en) Compositions and methods of treatment